Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | PHASE2 | COMPLETED | 80 | — | — | Feb 1, 2004 | Dec 1, 2006 | Dec 18, 2014 | 18 | United States |
| Name | Type | Description |
|---|---|---|
| SGN-30 (anti-CD30 mAb) | DRUG | - |
Inclusion Criteria: * Patients must have refractory or recurrent HD or refractory or recurrent ALCL. * Patients must have histologically confirmed CD30+ HD or ALCL. * Patients must have bidimensional measurable disease on physical examination or radiologic evaluation. * Patients must have failed sy...